Tai'ai (telitacicept) / Rongchang Pharma, Vor Biopharma - LARVOL DELTA

Treatment of Lupus Retinopathy With the Combination of Telitacicept and Methylprednisolone: A Case Report. (PubMed, Int J Rheum Dis) - No abstract available

Journal • Immunology • Inflammatory Arthritis • Lupus • Retinal Disorders • Systemic Lupus Erythematosus

A pilot study of telitacicept in predominantly immune-mediated necrotizing myopathy, retrospective analysis of a monocentric Chinese cohort. (PubMed, J Neurol) - "Telitacicept may be an effective and safety-promising therapeutic option for IIM, especially IMNM patients. Larger randomized controlled trials are required to confirm these findings."

Journal • Retrospective data • Immunology • Myositis

Novel Sequential Therapy with Obinutuzumab and Telitacicept in Severe Lupus Nephritis with Glucocorticoid-Induced Avascular Necrosis (AVN) of the Femoral Head: A Case Report. (PubMed, Am J Case Rep) - "CASE REPORT We report the case of a 22-year-old woman with biopsy-proven class V LN 6 years ago, initially managed with prednisone, tacrolimus, and hydroxychloroquine. CONCLUSIONS This is the first reported case of severe SLE treated with sequential therapy involving Obinutuzumab followed by telitacicept. The combination therapy of B-cell depletion plus BAFF/APRIL inhibition could be a promising and rational treatment approach for SLE patients, especially those with severe SLE, which warrants further clinical trials to validate the efficacy and safety of the therapeutic regimen."

Journal • Diabetes • Glomerulonephritis • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Lupus • Lupus Nephritis • Metabolic Disorders • Nephrology • Systemic Lupus Erythematosus

A case report of telitacicept in the treatment of immunocompromised and refractory lupus nephritis. (PubMed, Front Immunol) - "After anti-infective therapy, the treatment plan for glucocorticoids combined with telitacicept was individualized based on the patient's immune status, and the disease was quickly controlled. Simultaneously, it demonstrated efficacy and safety during follow-up, suggesting that telitacicept may be a new treatment option for refractory LN."

Journal • Glomerulonephritis • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Pneumonia • Respiratory Diseases • Systemic Lupus Erythematosus

Case Report: Telitacicept for interstitial lung disease associated with idiopathic inflammatory myopathies: an observational study. (PubMed, Front Pharmacol) - "Four patients with severe ILD were treated with a combination of rituximab (RTX) (375 mg/m2/week for 4 weeks) and telitacicept (160 mg/week). One patient was administered additional nintedanib for pulmonary fibrosis due to insufficient improvement in lung function. Telitacicept demonstrates substantial clinical efficacy in the treatment of IIM-associated ILD, accompanied by a low infection rate and a favorable safety profile."

Journal • Observational data • Dermatomyositis • Immunology • Infectious Disease • Interstitial Lung Disease • Musculoskeletal Pain • Myositis • Pain • Pulmonary Disease • Rare Diseases • Respiratory Diseases • IFIH1

Early-onset systemic lupus erythematosus in a patient with an inborn error of immunity caused by a NRAS mutation and treated with telitacicept. (PubMed, Mol Cell Pediatr) - No abstract available

Journal • Immunology • Inflammatory Arthritis • Lupus • Neuroblastoma • Oncology • Solid Tumor • Systemic Lupus Erythematosus • NRAS

Effects of telitacicept and belimumab on systemic lupus erythematosus: a systematic review and meta-analysis. (PubMed, Sci Rep) - "Secondary outcomes included prednisone dose reduction, anti-dsDNA change, adverse events (AEs) and serious AEs. Dual inhibition of BLyS and APRIL by telitacicept may offer an effective option for reducing SLE activity. Further large-scale, long-term head-to-head trials are needed to confirm these findings."

Journal • Retrospective data • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG) (clinicaltrials.gov) - P3 | N=120 | Not yet recruiting | Sponsor: RemeGen Co., Ltd.

New P3 trial • CNS Disorders • Myasthenia Gravis

Efficacy and Safety of Low-Dose Telitacicept in Patients with Primary IgAN (KIDNEY WEEK 2025) - "In the Telitacicept group, a subset of cases combined with low-dose hydroxychloroquine or other non-corticosteroid IS agents. Blood IgG decrease (4/13) was the most common investigator-assessed treatment-related adverse event in the Telitacicept group Conclusion Low-dose telitacicept can reduce proteinuria in a safety profile in IgAN patients. Telitacicept treatment showed superior kidney protection efficacy compared with IS agents during the 8-month follow-up."

Clinical • Glomerulonephritis • IgA Nephropathy • Renal Disease

Successful Treatment of Refractory Severe Pemphigus With Telitacicept as Adjunctive Therapy: Two Case Reports. (PubMed, Int J Dermatol) - No abstract available

Journal • Dermatology • Immunology • Pemphigus Vulgaris

Biological targeted therapy for lupus nephritis-the role of BLYS and APRIL. (PubMed, Ren Fail) - "Recently, B-cell-targeting agents, including rituximab, belimumab, as well as telitacicept have shown promising efficacy and reduced side effects in LN treatment. Telitacicept, a novel biological agent, has been approved firstly effective for SLE treatment in China. This review focus on the role of BLYS and APRIL in LN development and progression, alongside clinical data on the targeted therapies of above biologicals."

Journal • Review • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Oncology • Systemic Lupus Erythematosus • TNFA

Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China. (PubMed, Lancet) - P1 | "This study suggests that allogeneic CAR NK-cell therapy is a potent option for treatment of autoimmune diseases and indicates that such a therapy might address limitations of current autologous CAR T-cell therapy, including manufacturing scale and time, access, safety, and cost."

Journal • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Oncology • Systemic Lupus Erythematosus

Efficacy and Safety of Telitacicept in Patients with IgAN: Results from Stage A of a Phase 3 Clinical Study (KIDNEY WEEK 2025) - "The incidence of serious AEs was lower with telitacicept versus placebo (2.5% vs 8.2%). Conclusion In patients with IgAN at high risk of progression, treatment with telitacicept for 39 weeks resulted in a rapid, substantial, and statistically significant reduction in proteinuria compared with placebo, with a favorable safety profile."

Clinical • Late-breaking abstract • P3 data • Glomerulonephritis • IgA Nephropathy • Infectious Disease • Respiratory Diseases

Efficacy and Safety of Telitacicept as Add-On Therapy to Oral Glucocorticoids in IgAN: Real-World Retrospective Study (KIDNEY WEEK 2025) - "Conclusion Telitacicept, when used as an add-on to oral glucocorticoids in IgAN, exhibited faster and greater reductions in proteinuria and hematuria, improved eGFR, and a favorable safety profile compared to oral glucocorticoid therapy. Percentage change in primary outcomes between the two groups during the follow-up period."

Real-world • Real-world evidence • Retrospective data • Glomerulonephritis • IgA Nephropathy • Renal Disease

Efficacy and Safety Evaluation of Telitacicept in IgAN (KIDNEY WEEK 2025) - "B. Patients treated with telitacicept alone (A group)."

Clinical • Glomerulonephritis • IgA Nephropathy • Lupus Nephritis • Nephrology • Renal Disease

Nefecon (Targeted-Release Formulation of Budesonide) for IgAN: Two Case Reports (KIDNEY WEEK 2025) - "Initial treatment included methylprednisolone, prednisone, and telitacicept...The patient received irbesartan and entecavir...Discussion These cases highlight the potential of Nefecon as an effective therapy for IgAN, even in patients with advanced histologic damage and impaired renal function. The observed clinical benefits, including reduction in proteinuria and stabilization of renal function, supports its therapeutic value in real-world settings."

Case report • Clinical • Glomerulonephritis • Hepatitis B • Hepatology • IgA Nephropathy • Infectious Disease • Inflammation • Lupus Nephritis • Nephrology • Renal Disease

Efficacy and Safety of Telitacicept Combined with Low-Dosage Corticosteroids for IgA Vasculitis Nephropathy in Adults (KIDNEY WEEK 2025) - "All patients received subcutaneous injections of telitacicept (160 mg/week or 240 mg/week) combined with low-dose oral prednisone (starting dose: 0.3–0.5 mg/kg/day, maximum dose: 30 mg/day) for at least 3 months. No severe adverse events were reported, with treatment-related injection site reactions occurring in 2 patients. Conclusion Telitacicept combined with low-dose corticosteroids might be a promising treatment option for adult IgAVN patients."

Clinical • Glomerulonephritis • IgA Nephropathy • Nephrology • Renal Disease • Vasculitis

Single-Arm, Prospective, Multicenter Clinical Trial to Evaluate the Efficacy of Low-Dosage Administration of Telitacicept in IgAN (KIDNEY WEEK 2025) - "Figure 2. The change of immunoglobin A(A), G(B) and M(C) through time."

Clinical • Glomerulonephritis • IgA Nephropathy • Renal Disease

Successful Treatment of Rheumatoid Arthritis Complicated with Myasthenia Gravis by Telitacicept: A Case Report. (PubMed, Mod Rheumatol Case Rep) - "This is the first report on the treatment of rheumatoid arthritis complicated with myasthenia gravis by telitacicept. Meanwhile, the application of telitacicept in the treatment of this disease deserves further research and attention."

Journal • CNS Disorders • Immunology • Inflammatory Arthritis • Myasthenia Gravis • Rheumatoid Arthritis • Rheumatology

Efficacy and safety of telitacicept in the treatment of pediatric IgA nephropathy: a retrospective study. (PubMed, Pediatr Nephrol) - "Telitacicept has exhibited both effectiveness and safety in the treatment of children diagnosed with IgAN."

Journal • Retrospective data • Glomerulonephritis • IgA Nephropathy • Pediatrics • Renal Disease

Juvenile systemic lupus erythematosus complicated with posterior reversible encephalopathy syndrome: a case report and literature review. (PubMed, Orphanet J Rare Dis) - "Various factors can lead to complications of PRES in paediatric patients with systemic lupus erythematosus. In our patient, the likely cause was the high disease activity of SLE. This review revealed that juvenile SLE cases accompanied by PRES are often associated with lupus nephritis, hypertension, and high disease activity. Most patients recover with timely and active treatment, with only a few experiencing recurrence."

Journal • Review • Cardiovascular • CNS Disorders • Epilepsy • Glomerulonephritis • Hypertension • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Pain • Pediatrics • Systemic Lupus Erythematosus

The efficacy, safety, and pharmacokinetics/pharmacodynamics of telitacicept following efgartigimod in generalized myasthenia gravis: protocol of a randomized controlled trial. (PubMed, Front Immunol) - P=N/A | "Results of the study will be disseminated to the relevant scientific, clinical and patient communities on trial closure. Trial registration number: The study was registered at ClinicalTrials.gov (NCT06827587)."

Clinical protocol • Journal • PK/PD data • CNS Disorders • Myasthenia Gravis

Efficacy and Safety of Telitacicept in the Treatment of Systemic Lupus Erythematosus: A Single-Center Clinical Study (ChiCTR) - P=N/A | N=100 | Not yet recruiting | Sponsor: The Second Affiliated Hospital of Shantou University Medical College; The Second Affiliated Hospital of Shantou University Medical College

New trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Comparing Efficacy and Safety of Telitacicept and Belimumab in Systemic Lupus Erythematosus: A Retrospective Multicenter Cohort Study (ChiCTR) - P4 | N=180 | Not yet recruiting | Sponsor: Shandong Provincial Qianfoshan Hospital; Shandong Provincial Qianfoshan Hospital

New P4 trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Evaluation of the Efficacy and Safety of Telitacicept in IgA Nephropathy Patients with High-Grade Proteinuria Across Different Pathological Stages (ChiCTR) - P4 | N=100 | Not yet recruiting | Sponsor: The Second Affiliated Hospital of Shantou University Medical College; The Second Affiliated Hospital of Shantou University Medical College

New P4 trial • Glomerulonephritis • IgA Nephropathy • Renal Disease